A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations.

Register Today!

Trial Information

Start DateMarch 2023
End DateTBD
Trial Duration52 Weeks
Number of Visits~23

For additional information
on this trial contact: